Experiment 66782
Worktypes
Compounds isolated
Details
| Property | Value |
|---|---|
| Pharmacology | |
| Administration route | ORAL |
| Organism | Empty organism |
| Citation | MOLLER,HJ: ULM,K: GLOGGLER,A:. (1992). KAVAIN AS AN AID IN THE WITHDRAWAL OF BENZODIAZEPINES.. 134(37) |
| Amount utilized | |
| Compound isolated | |
| Disease | KAVAIN AS AN AID IN THE WITHDRAWAL OF BENZODIAZEPINES. EXAMINATION OF THE ANXIOLYTIC POTENCY OF D, L-KAVAIN IN THE SUBSTITUTION OF CHRONIC BENZODIAZEPINE MEDICATION. PLACEBO-CONTROLLED, DOUBLE-BLIND RANDOMISED STUDY IN 12 PSYCHIATRIC PRACTICES. 83 OUTPATIENTS HAVING UNDERGONE AT LEAST 6 WEEKS BENZODIAZEPINE TREATMENT FOR NEUROTIC ANXIETY SYNDROMES. 1 CAPSULES OF 200 MG KAVAIN OR 1 PLACEBO CAPSULE THREE TIMES DAILY DURING 3 WEEKS OF GRADUAL BENZODIAZEPINE WITHDRAWAL AND 3 WEEKS OF FOLLOW-UP. OVERALL CLINICAL ASSESSMENT AND STANDARDISED ANXIETY RATING SCALES. (ASI, SAS). ACCORDING TO THE OVERALL CLINICAL ASSESSMENT SIGNIFICANTL ADVANTAGE IN FAVOUR OF KAVAIN AFTER THE 3RD WEEK (FOLLOWING A 75% REDUCTION OF THE BENZODIAZEPINE DOSE) UP UNTIL THE END OF THE FOLLOOW-UP (3 WEEKS AFTER DISCONTINUING BENZODIAZEPINE); IN THE FINAL EXAMINATION LOWER ASI AND SAS SCORES AT 39 AND 41 UNDER KAVAIN AS COMPARED WITH 52 AND 48 IN THE PLACEBO GROUP (P<0.01 EACH). CLINICALLY RELEVANT EVIDENCE OF THE ANXIOLYTIC POTENCY OF KAVAIN IN THE WITHDRAWAL OF CHRONIC BENZODIAZEPINE MEDICATION. |
| Dose amount | 200.0 MG |
| Number | 1 |
| Qualitative result | ACTIVE |
| Animal | HUMAN ADULT |
| Per unit | DAY |
| Dose expression | DOSE |
| Gender | GIVEN TO BOTH SEXES |